Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer

World Journal of Clinical Oncology

Volumn 5, Issue 5, 2014, Pages 865-873

  Tsai, Meng Feng ^a   Wang, Chi Chung ^b   Chen, Jeremy J W ^c  

^a DA YEH UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Anticancer; Biomarker; HLJ1; Metastasis; Non small cell lung cancer

Indexed keywords

EID: 84939160078     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i5.865     Document Type: Article

References (95)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
3. Meoni G, Cecere FL, Lucherini E, Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol 2013; 4: 282-290 [PMID: 24070465 DOI: 10.1016/j.jgo.2013.04.005]
4. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299 [PMID: 15900604 DOI: 10.1002/ijc.21183]
5. Nakajima T, Yasufuku K. Early lung cancer: methods for detection. Clin Chest Med 2013; 34: 373-383 [PMID: 23993810 DOI: 10.1016/j.ccm.2013.04.005]
6. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594 [PMID: 18452692 DOI: 10.4065/83.5.584]
7. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biol 2009; 471: 469-486 [PMID: 19109795 DOI: 10.1007/978-1-59745-416-2-24]
8. Bearz A, Berretta M, Lleshi A, Tirelli U. Target therapies in lung cancer. J Biomed Biotechnol 2011; 2011: 921231 [PMID: 21541198 DOI: 10.1155/2011/921231]
9. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128: 452-462 [PMID: 16002972 DOI: 10.1378/chest.128.1.452]
10. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013; 382: 709-719 [PMID: 23972814 DOI: 10.1016/S0140-6736(13)61502-0]
11. Wao H, Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev 2013; 2: 10 [PMID: 23379753 DOI: 10.1186/2046-4053-2-10]
12. Meyer T, Hart IR. Mechanisms of tumour metastasis. Eur J Cancer 1998; 34: 214-221 [PMID: 9741324 DOI: 10.1016/S0959-8049(97)10129-0]
13. Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol 2011; 7: 1285-1297 [PMID: 22044203 DOI: 10.2217/fon.11.112]
14. Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol 2013; 87: 1-11 [PMID: 23332547 DOI: 10.1016/j.critrevonc.2012.12.007]
15. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 2008; 1786: 87-104 [PMID: 18692117 DOI: 10.1016/j. bbcan.2008.07.002]
16. Li DQ, Pakala SB, Nair SS, Eswaran J, Kumar R. Metastasisassociated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res 2012; 72: 387-394 [PMID: 22253283 DOI: 10.1158/0008-5472.CAN-11-2345]
17. Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, Yu CJ, Lin SB, Liou GY, Lee ML, Chen JJ, Hong TM, Yang SC, Su JL, Lee YC, Yang PC. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 2005; 11: 8070-8078 [PMID: 16299238 DOI: 10.1158/1078-0432.CCR-05-0687]
18. Pan SH, Chao YC, Hung PF, Chen HY, Yang SC, Chang YL, Wu CT, Chang CC, Wang WL, Chan WK, Wu YY, Che TF, Wang LK, Lin CY, Lee YC, Kuo ML, Lee CH, Chen JJ, Hong TM, Yang PC. The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. J Clin Invest 2011; 121: 3189-3205 [PMID: 21747164 DOI: 10.1172/JCI42975]
19. Tsai MF, Wang CC, Chang GC, Chen CY, Chen HY, Cheng CL, Yang YP, Wu CY, Shih FY, Liu CC, Lin HP, Jou YS, Lin SC, Lin CW, Chen WJ, Chan WK, Chen JJ, Yang PC. A new tumor suppressor DnaJ-like heat shock protein, HLJ1, and survival of patients with non-small-cell lung carcinoma. J Natl Cancer Inst 2006; 98: 825-838 [PMID: 16788156 DOI: 10.1093/jnci/djj229]
20. Wang CC, Tsai MF, Hong TM, Chang GC, Chen CY, Yang WM, Chen JJ, Yang PC. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene 2005; 24: 4081-4093 [PMID: 15782117 DOI: 10.1038/sj.onc.1208573]
21. Wang CC, Tsai MF, Dai TH, Hong TM, Chan WK, Chen JJ, Yang PC. Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. Cancer Res 2007; 67: 4816-4826 [PMID: 17510411 DOI: 10.1158/0008-5472.CAN-07-0504]
22. Chang TP, Yu SL, Lin SY, Hsiao YJ, Chang GC, Yang PC, Chen JJ. Tumor suppressor HLJ1 binds and functionally alters nucleophosmin via activating enhancer binding protein 2alpha complex formation. Cancer Res 2010; 70: 1656-1667 [PMID: 20145123 DOI: 10.1158/0008-5472.CAN-09-2453]
23. Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, Su SF, Huang CW, Ho CC, Chen JJ, Tsai MF, Yu SL, Yang PC. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 2008; 68: 7428-7438 [PMID: 18794131 DOI: 10.1158/0008-5472. CAN-07-6734]
24. Ritossa F. Discovery of the heat shock response. Cell Stress Chaperones 1996; 1: 97-98 [PMID: 9222594]
25. Vabulas RM, Raychaudhuri S, Hayer-Hartl M, Hartl FU. Protein folding in the cytoplasm and the heat shock response. Cold Spring Harb Perspect Biol 2010; 2: a004390 [PMID: 21123396 DOI: 10.1101/cshperspect.a004390]
26. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet 1988; 22: 631-677 [PMID: 2853609 DOI: 10.1146/annurev. ge.22.120188.003215]
27. Colaco CA, Bailey CR, Walker KB, Keeble J. Heat shock proteins: stimulators of innate and acquired immunity. Biomed Res Int 2013; 2013: 461230 [PMID: 23762847 DOI: 10.1155/2013/461230]
28. Helmbrecht K, Zeise E, Rensing L. Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 2000; 33: 341-365 [PMID: 11101008 DOI: 10.1046/j.1365-2184.2000.00189.x]
29. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92: 1564-1572 [PMID: 11018092 DOI: 10.1093/jnci/92.19.1564]
30. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta 2011; 1816: 89-104 [PMID: 21605630 DOI: 10.1016/j.bbcan.2011.05.001]
31. Miyata Y, Nakamoto H, Neckers L. The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 2013; 19: 347-365 [PMID: 22920906 DOI: 10.2174/1381612811306030347]
32. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett 2013; 23: 1923-1928 [PMID: 23453837 DOI: 10.1016/j.bmcl.2013.02.014]
33. Li J, Qian X, Sha B. Heat shock protein 40: structural studies and their functional implications. Protein Pept Lett 2009; 16: 606-612 [PMID: 19519518 DOI: 10.2174/092986609788490159]
34. Sterrenberg JN, Blatch GL, Edkins AL. Human DNAJ in cancer and stem cells. Cancer Lett 2011; 312: 129-142 [PMID: 21925790 DOI: 10.1016/j.canlet.2011.08.019]
35. Qiu XB, Shao YM, Miao S, Wang L. The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 2006; 63: 2560-2570 [PMID: 16952052 DOI: 10.1007/s00018-006-6192-6]
36. Chen CY, Jan CI, Lo JF, Yang SC, Chang YL, Pan SH, Wang WL, Hong TM, Yang PC. Tid1-L inhibits EGFR signaling in lung adenocarcinoma by enhancing EGFR Ubiquitinylation and degradation. Cancer Res 2013; 73: 4009-4019 [PMID: 23698466 DOI: 10.1158/0008-5472.CAN-12-4066]
37. Copeland E, Balgobin S, Lee CM, Rozakis-Adcock M. hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas. Oncogene 2011; 30: 2252-2263 [PMID: 21242965 DOI: 10.1038/onc.2010.601]
38. Chen CY, Chiou SH, Huang CY, Jan CI, Lin SC, Hu WY, Chou SH, Liu CJ, Lo JF. Tid1 functions as a tumour suppressor in head and neck squamous cell carcinoma. J Pathol 2009; 219: 347-355 [PMID: 19681071 DOI: 10.1002/path.2604]
39. Trentin GA, Yin X, Tahir S, Lhotak S, Farhang-Fallah J, Li Y, Rozakis-Adcock M. A mouse homologue of the Drosophila tumor suppressor l(2)tid gene defines a novel Ras GTPaseactivating protein (RasGAP)-binding protein. J Biol Chem 2001; 276: 13087-13095 [PMID: 11116152 DOI: 10.1074/jbc. M009267200]
40. Ahn BY, Trinh DL, Zajchowski LD, Lee B, Elwi AN, Kim SW. Tid1 is a new regulator of p53 mitochondrial transloca-tion and apoptosis in cancer. Oncogene 2010; 29: 1155-1166 [PMID: 19935715 DOI: 10.1038/onc.2009.413]
41. Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res 2008; 10: R22 [PMID: 18328103 DOI: 10.1186/bcr1874]
42. Mitra A, Menezes ME, Shevde LA, Samant RS. DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. J Biol Chem 2010; 285: 24686-24694 [PMID: 20522561 DOI: 10.1074/jbc.M109.094847]
43. Hatle KM, Neveu W, Dienz O, Rymarchyk S, Barrantes R, Hale S, Farley N, Lounsbury KM, Bond JP, Taatjes D, Rincón M. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol Cell Biol 2007; 27: 2952-2966 [PMID: 17283040 DOI: 10.1128/MCB.01804-06]
44. Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A. Potential markers for detection and monitoring of ovarian cancer. J Oncol 2011; 2011: 475983 [PMID: 21577260 DOI: 10.1155/2011/475983]
45. Witham J, Vidot S, Agarwal R, Kaye SB, Richardson A. Transient ectopic expression as a method to detect genes conferring drug resistance. Int J Cancer 2008; 122: 2641-2645 [PMID: 18324624 DOI: 10.1002/ijc.23427]
46. Hoe KL, Won M, Chung KS, Jang YJ, Lee SB, Kim DU, Lee JW, Yun JH, Yoo HS. Isolation of a new member of DnaJlike heat shock protein 40 (Hsp40) from human liver. Biochim Biophys Acta 1998; 1383: 4-8 [PMID: 9546042 DOI: 10.1016/S0167-4838(97)00207-0]
47. Ohtsuka K, Hata M. Molecular chaperone function of mammalian Hsp70 and Hsp40-a review. Int J Hyperthermia 2000; 16: 231-245 [PMID: 10830586]
48. Uchiyama Y, Takeda N, Mori M, Terada K. Heat shock protein 40/DjB1 is required for thermotolerance in early phase. J Biochem 2006; 140: 805-812 [PMID: 17050614 DOI: 10.1093/jb/mvj212]
49. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997; 17: 353-360 [PMID: 9308922 DOI: 10.1165/ajrcmb.17.3.2837]
50. Chen JJ, Peck K, Hong TM, Yang SC, Sher YP, Shih JY, Wu R, Cheng JL, Roffler SR, Wu CW, Yang PC. Global analysis of gene expression in invasion by a lung cancer model. Cancer Res 2001; 61: 5223-5230 [PMID: 11431363]
51. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11-20 [PMID: 17202451 DOI: 10.1056/NEJMoa060096]
52. Kim KJ, Ahn YC, Lim do H, Han J, Park K, Park JO, Kim K, Kim J, Shim YM. Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer 2007; 55: 329-336 [PMID: 17157950 DOI: 10.1016/j.lungcan.2006.10.024]
53. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999; 79: 1468-1474 [PMID: 10188892 DOI: 10.1038/sj.bjc.6690234]
54. Canel M, Serrels A, Frame MC, Brunton VG. E-cadherinintegrin crosstalk in cancer invasion and metastasis. J Cell Sci 2013; 126: 393-401 [PMID: 23525005 DOI: 10.1242/jcs.100115]
55. Simões-Correia J, Silva DI, Melo S, Figueiredo J, Caldeira J, Pinto MT, Girão H, Pereira P, Seruca R. DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo. Hum Mol Genet 2014; 23: 2094-2105 [PMID: 24293545 DOI: 10.1093/hmg/ddt602]
56. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6: 493-505 [PMID: 16794633 DOI: 10.1038/nrc1885]
57. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379-390 [PMID: 2914325 DOI: 10.1016/0092-867 4(89)90241-9]
58. Li J, Sejas DP, Burma S, Chen DJ, Pang Q. Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability. Carcinogenesis 2007; 28: 1163-1170 [PMID: 17277230 DOI: 10.1093/carcin/bgm025]
59. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
60. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101: 227-257 [PMID: 15031001 DOI: 10.1016/j.pharmthera.2003.11.004]
61. Lin SY, Hsueh CM, Yu SL, Su CC, Shum WY, Yeh KC, Chang GC, Chen JJ. HLJ1 is a novel caspase-3 substrate and its expression enhances UV-induced apoptosis in non-small cell lung carcinoma. Nucleic Acids Res 2010; 38: 6148-6158 [PMID: 20494979 DOI: 10.1093/nar/gkq412]
62. Galvin KM, Shi Y. Multiple mechanisms of transcriptional repression by YY1. Mol Cell Biol 1997; 17: 3723-3732 [PMID: 9199306]
63. Yao YL, Yang WM, Seto E. Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 2001; 21: 5979-5991 [PMID: 11486036 DOI: 10.1128/MCB.21.17.597]
64. Wang CC, Chen JJ, Yang PC. Multifunctional transcription factor YY1: a therapeutic target in human cancer? Expert Opin Ther Targets 2006; 10: 253-266 [PMID: 16548774 DOI: 10.1517/14728222.10.2.253]
65. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009; 8: 1367-1372 [PMID: 19342874 DOI: 10.4161/cc.8.9.8314]
66. Zhang Q, Stovall DB, Inoue K, Sui G. The oncogenic role of Yin Yang 1. Crit Rev Oncog 2011; 16: 163-197 [PMID: 22248053 DOI: 10.1615/CritRevOncog.v16.i3-4.30]
67. Lara-Pezzi E, Gómez-Gaviro MV, Gálvez BG, Mira E, Iñiguez MA, Fresno M, Martínez-A C, Arroyo AG, López-Cabrera M. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002; 110: 1831-1838 [PMID: 12488433 DOI: 10.1172/JCI15887]
68. Liu LP, Liang HF, Chen XP, Zhang WG, Yang SL, Xu T, Ren L. The role of NF-kappaB in Hepatitis b virus X proteinmediated upregulation of VEGF and MMPs. Cancer Invest 2010; 28: 443-451 [PMID: 20073580 DOI: 10.3109/0735790090 3405959]
69. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, Kim CW, Kim KW. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004; 18: 382-384 [PMID: 14688211 DOI: 10.1096/fj.03-0153fje]
70. Zhang L, Cai X, Chen K, Wang Z, Wang L, Ren M, Huang A, Tang H. Hepatitis B virus protein up-regulated HLJ1 expression via the transcription factor YY1 in human hepatocarcinoma cells. Virus Res 2011; 157: 76-81
71. Gautam SC, Gao X, Dulchavsky S. Immunomodulation by curcumin. Adv Exp Med Biol 2007; 595: 321-341 [PMID: 17569218 DOI: 10.1007/978-0-387-46401-5-14]
72. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 2008; 52: 1010-1030 [PMID: 18384098 DOI: 10.1002/mnfr.200700354]
73. Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des 2013; 19: 2047-2069 [PMID: 23116312 DOI: 10.2174/1381612811319110 007]
74. Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT, Yang PC. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol 2004; 65: 99-110 [PMID: 14722241 DOI: 10.1124/mol.65.1.99]
75. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2006; 25: 278-287 [PMID: 16170359 DOI: 10.1038/sj.onc.1209019]
76. Chen QY, Zheng Y, Jiao DM, Chen FY, Hu HZ, Wu YQ, Song J, Yan J, Wu LJ, Lv GY. Curcumin inhibits lung cancer cell migration and invasion through Rac1-dependent signaling pathway. J Nutr Biochem 2014; 25: 177-185 [PMID: 24445042 DOI: 10.1016/j.jnutbio.2013.10.004]
77. Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene 2003; 22: 5619-5629 [PMID: 12944910 DOI: 10.1038/sj.onc.1206644]
78. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc Natl Acad Sci USA 1991; 88: 5292-5296 [PMID: 1905019 DOI: 10.1073/pnas.88.12.5292]
79. Santos NC, Martins-Silva J, Saldanha C. PTEN "meets" DMSO. Leuk Res 2005; 29: 361-362 [PMID: 15725467 DOI: 10.1016/j.leukres.2004.09.009]
80. Pegg DE. Principles of cryopreservation. Methods Mol Biol 2007; 368: 39-57 [PMID: 18080461 DOI: 10.1007/978-1-59745-362-2-3]
81. Parkin J, Shea C, Sant GR. Intravesical dimethyl sulfoxide (DMSO) for interstitial cystitis-a practical approach. Urology 1997; 49: 105-107 [PMID: 9146010]
82. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65: 1035-1041 [PMID: 12663039 DOI: 10.1016/S0006-2952(03)00002-9]
83. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 1978; 75: 2458-2462 [PMID: 276884 DOI: 10.1073/pnas.75.5.2458]
84. Teraoka H, Mikoshiba M, Takase K, Yamamoto K, Tsukada K. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells. Exp Cell Res 1996; 222: 218-224 [PMID: 8549666 DOI: 10.1006/excr.1996.0027]
85. Chang CK, Albarillo MV, Schumer W. Therapeutic effect of dimethyl sulfoxide on ICAM-1 gene expression and activation of NF-kappaB and AP-1 in septic rats. J Surg Res 2001; 95: 181-187 [PMID: 11162043 DOI: 10.1006/jsre.2000.6033]
86. Wang CC, Lin SY, Lai YH, Liu YJ, Hsu YL, Chen JJ. Dimethyl sulfoxide promotes the multiple functions of the tumor suppressor HLJ1 through activator protein-1 activation in NSCLC cells. PLoS One 2012; 7: e33772 [PMID: 22529897 DOI: 10.1371/journal.pone.0033772]
87. Sideris DA, Toumanidis ST, Kostis EB, Stagiannis K, Spyropoulos G, Moulopoulos SD. Response of tertiary centres to pressure changes. Is there a mechano-electrical association? Cardiovasc Res 1990; 24: 13-18 [PMID: 2328509 DOI: 10.1371/journal.pone.0052572]
88. Tang FY, Cho HJ, Pai MH, Chen YH. Concomitant supplementation of lycopene and eicosapentaenoic acid inhibits the proliferation of human colon cancer cells. J Nutr Biochem 2009; 20: 426-434 [PMID: 18708285 DOI: 10.1016/j. jnutbio. 2008.05.001]
89. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004; 215: 129-140 [PMID: 15488631 DOI: 10.1016/j.canlet.2004.07.013]
90. Lai YH, Yu SL, Chen HY, Wang CC, Chen HW, Chen JJ. The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer. Carcinogenesis 2013; 34: 1069-1080 [PMID: 23306212 DOI: 10.1093/carcin/bgt005]
91. Sheeja K, Guruvayoorappan C, Kuttan G. Antiangiogenic activity of Andrographis paniculata extract and andrographolide. Int Immunopharmacol 2007; 7: 211-221 [PMID: 17178389 DOI: 10.1016/j.intimp.2006.10.002]
92. Chandrasekaran CV, Thiyagarajan P, Sundarajan K, Goudar KS, Deepak M, Murali B, Allan JJ, Agarwal A. Evaluation of the genotoxic potential and acute oral toxicity of standardized extract of Andrographis paniculata (KalmCold). Food Chem Toxicol 2009; 47: 1892-1902 [PMID: 19447157]
93. Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A, Chanchareon U. Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. J Clin Pharm Ther 2004; 29: 37-45 [PMID: 14748896 DOI: 10.1046/j.1365-2710.2003.00534.x]
94. Shi MD, Lin HH, Chiang TA, Tsai LY, Tsai SM, Lee YC, Chen JH. Andrographolide could inhibit human colorectal carcinoma Lovo cells migration and invasion via downregulation of MMP-7 expression. Chem Biol Interact 2009; 180: 344-352 [PMID: 19426720 DOI: 10.1016/j.cbi.2009.04.011.]
95. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol 2010; 632: 23-32 [PMID: 20097193 DOI: 10.1016/j. ejphar.2010.01.009]